Main image Main image

Cend Therapeutics in the News

August 16, 2019



Event: ESMO European Society for Medical Oncology
Dates: Sep 27, 2019 – Oct 1, 2019
Location: Barcelona, Spain

Event: Bionetwork 2019
Dates: Oct 23 – 25, 2019
Location: The Ritz-Carlton Laguna Niguel, CA



Event: BIO Europe 2019
Dates: Nov 11–13, 2019
Location: Hamburg, Germany

Event: JP Morgan 38th Annual Healthcare Conference
Dates: Jan 13-16, 2020
Location: San Francisco

June 12, 2019

Only a tiny fraction of T cells can infiltrate solid tumors. A new independent Nature Communications study shows how DrugCendR’s molecular mimicry technology can open up cancer tissues and potentially overcome the barriers for a broad range of immunotherapies such as anti-PD-1 and CAR-T cells. The open access paper: https://www.nature.com/articles/s41467-019-09296-6

 

April 7, 2019

(Kyoto, Japan / La Jolla, CA) – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “Kyoto-iCAP”) and DrugCendR Inc. (Headquarters: La Jolla, CA, US; President and CEO: Erkki Ruoslahti; “DrugCendR”) today jointly announced that it has concluded a multimillion-dollar investment in DrugCendR, to accelerate the global development of DrugCendR’s breakthrough tumor penetrating technology.


“I am delighted to announce the completion of the strategic investment in DrugCendR Inc. We, Kyoto-iCAP, will continue to support the development of DrugCendR’s technologies in the long term.”said Koji Murota, CEO of Kyoto-iCAP.

“This investment into DrugCendR Inc. by Kyoto-iCAP and Kyoto University will allow us to complete our ongoing phase 1 clinical trial on the lead compound of the company” stated Dr. Erkki Ruoslahti, M.D., Ph.D., President and CEO of DrugCendR. “The strategic relationship with the fund and Kyoto University, a preeminent university in the world, will be important for us into the future. We will also collaborate with clinical researchers led by Dr. Yoshiharu Sakai, M.D., Ph.D., Professor of Surgery on clinical studies the university is uniquely equipped to perform. We hope to provide new treatment options for cancer patients in the US, Japan and elsewhere in the world.”


Concurrent with the investment, DrugCendR will initiate non-clinical and clinical research collaboration with Kyoto University. Professor Yoshiharu Sakai, M.D., Ph.D., Gastrointestinal Surgery, Department of Surgery, Kyoto University and Associate Professor Kazutaka Obama, M.D., Ph.D. will lead the collaboration for Kyoto University.